AP Biosciences, Tasly Finalize Collaboration Agreement

AP Biosciences and Tasly have concluded an amended collaboration agreement focused on the global out-licensing of AP505 (B1962). This strategic partnership aims to broaden the international reach and accessibility of this promising cancer therapy. The agreement underscores a shared commitment to advancing oncology treatments and making them available to a wider patient population worldwide. Both companies are dedicated to leveraging their combined expertise to accelerate the development and commercialization of innovative biopharmaceutical solutions.